Nimrata  Hunt net worth and biography

Nimrata Hunt Biography and Net Worth

Dr. Hunt has been an Executive Vice President of IDEXX and the General Manager of Point of Care Diagnostics, and Worldwide Operations since January 2020. Prior to that, she served as a Corporate Vice President at IDEXX from November 2016 to January 2020, with a portfolio that included the company’s IDEXX VetLab, Diagnostic Imaging, and Telemedicine businesses. Dr. Hunt joined IDEXX in 2006 and served in various leadership roles in support of the company’s robust innovation pipeline, most recently leading the IDEXX VetLab organization as General Manager. In this role, she led development of market-leading veterinary diagnostic analyzers and assays for a growing and increasingly complex global market. Prior to joining IDEXX, Dr. Hunt served as Vice President at Woodard Curran, where she led the firm's litigation support practice. She holds a PhD in environmental engineering from Purdue University, an MBA from the University of Southern Maine, and is a graduate of the Stanford University Graduate School of Business’s Executive Education Program.

How do I contact Nimrata Hunt?

The corporate mailing address for Dr. Hunt and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Nimrata Hunt's contact information.

Has Nimrata Hunt been buying or selling shares of IDEXX Laboratories?

Nimrata Hunt has not been actively trading shares of IDEXX Laboratories during the last ninety days. Most recently, Nimrata Hunt sold 538 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $703.00, for a transaction totalling $378,214.00. Learn More on Nimrata Hunt's trading history.

Who are IDEXX Laboratories' active insiders?

IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.

Are insiders buying or selling shares of IDEXX Laboratories?

During the last year, insiders at the sold shares 6 times. They sold a total of 62,488 shares worth more than $34,708,688.36. The most recent insider tranaction occured on May, 17th when Director Bruce L Claflin sold 200 shares worth more than $108,160.00. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.

Information on this page was last updated on 5/17/2024.

Nimrata Hunt Insider Trading History at IDEXX Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2021Sell538$703.00$378,214.00View SEC Filing Icon  
11/5/2020Sell2,098$470.08$986,227.84View SEC Filing Icon  
8/14/2020Sell2,776$377.50$1,047,940.00View SEC Filing Icon  
See Full Table

Nimrata Hunt Buying and Selling Activity at IDEXX Laboratories

This chart shows Nimrata Hunt's buying and selling at IDEXX Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IDEXX Laboratories Company Overview

IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $411.10
Low: $398.50
High: $411.80

50 Day Range

MA: $464.08
Low: $406.92
High: $517.06

2 Week Range

Now: $411.10
Low: $398.50
High: $583.39

Volume

75,315 shs

Average Volume

501,371 shs

Market Capitalization

$33.66 billion

P/E Ratio

39.64

Dividend Yield

N/A

Beta

1.36